A phase 1 study of
DNIB 0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC).
For TDMA slot assignment
DNIB [32] algorithm is used and for FDMA slot assignment, HyMAC algorithm is used.
Its predecessor, De Nationale Investeringsbank, (
DNIB) has been an intermediary for EIB global loans in the Netherlands for over ten years.